Haleon plc (HLN)
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc has a collaboration agreement with Microsoft to scale digital, data and AI capabilities across the business and accelerate delivery of its global win as one strategy. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
- Symbol
- HLN
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- 52 week range
- 8.65 - 11.28
Valuation
- Share price
- $9.11 (close of 2026-09-23)
- P/E (TTM)
- 18.51x
- Price to book
- 1.88x
- Price to free cash flow
- 13.37x
Price performance
| Period | Change |
|---|---|
| 1 day | -2.67% |
| 5 days | -1.41% |
| 1 month | -8.90% |
| 3 months | +1.79% |
| 6 months | -8.26% |
| Year to date | -9.89% |
| 1 year | +2.02% |
| 3 years | +11.78% |
| All time | +24.79% |
Profitability and growth
- Return on equity
- 10.11%
- Return on invested capital
- 8.17%
- Return on assets
- 5.11%
- Return on capital employed
- 8.71%
- Gross margin
- 64.19%
- Net margin
- 15.11%
- EBITDA margin
- 25.13%
- Revenue growth
- -1.81%
- Net income growth
- 15.60%
- Free cash flow growth
- 12.73%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 7.48%
- Current ratio
- 0.92x
- Net debt to EBITDA
- 2.54x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Shares outstanding
- 4.49B
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2025-12-31 | 64.19% | 15.11% | 10.11% | 8.17% |
| 2024-12-31 | 60.75% | 12.84% | 8.89% | 7.36% |
| 2023-12-31 | 59.70% | 9.28% | 6.27% | 5.89% |
| 2022-12-31 | 60.57% | 9.76% | 6.44% | 5.06% |
| 2021-12-31 | 62.34% | 14.56% | 5.25% | 5.51% |
| 2020-12-31 | 59.75% | 11.58% | 4.37% | 4.59% |
Investor relations
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-07-30 | Jun/2026 | - |
| 2025-02-27 | - | - |
| 2024-10-31 | - | - |
| 2024-08-01 | - | - |
| 2024-05-01 | - | - |
| 2024-02-29 | - | - |
| 2023-11-02 | - | - |
| 2023-08-02 | - | - |
Filings and sources
- Company website
- haleon.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Zoetis Inc. (ZTS) · Viatris Inc (VTRS) · Hims & Hers Health, Inc. (HIMS) · Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH)
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades